Exchange: NASDAQ·Updated 07:36 PM EDT

VTRS News

News
all
press releases
4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats
VTRS, RVTY, ELAN and VCYT have earnings beat signals ahead of Q3 results. Can drug launches, lab spending and cancer tests overcome margin pressures?
Zacks
4 Medical Stocks With a Healthy Shot at Q3 Earnings Beats
VTRS, RVTY, ELAN and VCYT have earnings beat signals ahead of Q3 results. Can drug launches, lab spending and cancer tests overcome margin pressures?
Zacks
More News
Why Did MA, LNG, VTRS Stocks Surge To 52-Week Highs?
Mastercard, Cheniere Energy and Viatris shares climbed to annual highs on Thursday amid strong quarterly results and positive company catalysts.
Stocktwits
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?
Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Why Did XOM, BTE, VTRS Jump To 52-Week Highs Today?
ExxonMobil, Baytex Energy and Viatris have risen to 52-week highs amid soaring energy prices and Wall Street optimism around the companies.
Stocktwits
Will Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?
Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Zacks
IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave
ImmunityBio expects November results from a 366-patient Anktiva trial and plans a fourth-quarter FDA filing.
Stocktwits
Why Viatris (VTRS) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Here's Why Viatris (VTRS) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks
Viatris Receives U.S. FDA Approval for RYZUMVI for the Treatment of Presbyopia
Viatris Receives U.S. FDA Approval for RYZUMVI for the Treatment of Presbyopia Viatris Receives U.S. FDA Approval for RYZUMVI for the Treatment of PresbyopiaPR NewswirePITTSBURGH, Oct. 16, 2026 PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc.(Nasdaq: VTRS), a global healthcare company, today...
PR Newswire
Opus Genetics Secures FDA Approval For Eye Drops – Set To Receive Milestone Payment
The approval expands the therapy's use and triggers a milestone payment from commercial partner Viatris.
Stocktwits

Advertisement|Remove ads.